"We are very excited about the potential to create a subcu version of Daratumumab. This is based on an agreement between Janssen in December and Halozyme, the only clinical consolidated technology to infuse large amounts of therapeutic proteins in patients. You can thus reduce a three to four hour infusion potentially to a less than 10 minutes infusion subcutaneously. We think that there is huge impact when you believe that a drug like Daratumumab could be used in multiple lines of therapy Thomas.
This will have an impact, I think in maintenance setting in the smaller ring setting with the premalignant indication to high risks smaller ring setting. They will soon start up a clinical study and we believe this can be seen both as says life cycle management because you can then significantly expands the tail-end of the royalty income for both Janssen and Genmab and also to effectively ward off competition because this agreement is exclusively to CD-38. No other CD-38 antibody can use the clinically validated Halozyme technology and that has been secured by this agreement.
So it essentially locks out competing CD-38 antibodies from using this clinically validated subcu technology. And that can likely end up in much better tolerability of the drug, significant patient benefit because the infusion times are shorter, potentially a more benign, even more benign safety profile with this subcu version that will probably lead to a lower burden on the clinics for scheduling, because you can do infusions much more quickly.
So what I see and what we see together our development partners that this is a huge strategically typical potential expansion of a much bigger markets for having access to a subcu formulation. And we hope to start a probably phase 1 clinical study comparing the subcu with the IV formulations over the coming months and we are now finalizing those plans. I don't think I can say anything further."
From Seeking Alpha transcript for Genmab cc yesterday.
Never argue with a fool, for after awhile, it becomes difficult to determine which is the fool.
